At the ICG19·MH and MOHA Consortium, experts emphasized the growing potential of stool-based tests like COLOTECT for colorectal cancer (CRC) screening, addressing global challenges in accessing colonoscopy services. These tests offer improved accessibility and compliance. Additionally, discussions highlighted the potential of the gut microbiome in disease detection, with experts noting its future role in diagnosing conditions like CRC and Parkinson’s. Such innovations promise to make preventive healthcare more effective and accessible globally.
Keep Reading
Add A Comment